Zobrazeno 1 - 10
of 121
pro vyhledávání: '"Hirva, Mamdani"'
Autor:
Arkadiusz Z. Dudek, MD, PhD, Min X. Xi, PhD, Katherine A. Scilla, MD, Hirva Mamdani, MD, Benjamin C. Creelan, MD, Andreas Saltos, MD, Tawee Tanvetyanon, MD, Alberto Chiappori, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 12, Pp 100584- (2023)
Introduction: We hypothesized that ramucirumab could increase previously reported objective response rate (ORR) of 11% of single-agent nivolumab in the second-line therapy of unresectable mesothelioma. Methods: This was a cooperative group, single-ar
Externí odkaz:
https://doaj.org/article/0149c45692094f848ef9ee464ffa82d8
Autor:
Haven Garber, Saranya Chumsri, Yazan Migdady, Chul Kim, Erika Hamilton, Jennifer Specht, Babar Bashir, Hirva Mamdani, Heidi Gillenwater, Yeonhee Kim, David R Spigel, Usama Gergis, Hemant S Murthy, Lubna N Chaudhary, Sarah Fitzsimmons, Bishwa J Ganguly, Hajime Hiraragi, Helle Jensen, Mary C Lessig
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/22595beb19204c3fae68bc30f71d834e
Autor:
Cara Haymaker, Aung Naing, Minal Barve, Marya Chaney, Se Hwan Yang, Siyoung Lee, Byung Ha Lee, Sara Ferrando-Martinez, Hirva Mamdani, Richard D Kim, Meredith Pelster, Mohamed Derbala, Jack Goon, Samuel Darko, Julie Murphy, Lauren Gorelik, Allison Bierly
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/3834b1df978a4a97b72c5c4dae0c35d4
Autor:
Seongho Kim, Tarik Hadid, Hirva Mamdani, Khalil Choucair, Hyejong Jang, Shadia I Jalal, Dipesh Uprety
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/8eda68db52c741068a293ba62f127292
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/68607c2529b943a7bfb657b05f0015ee
Autor:
Yuman Fong, Amanda Seiz, Hirva Mamdani, Melissa Polasek, Daneng Li, Leslie Chong, Alexander I Spira, Jennifer Leddon, Seymour Fein, Nick Ede, Ursula McCurry, Sharon Yavrom, Giovanni Selvaggi
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/8d18a0d35fb643a68cee3c39228afbff
Autor:
Ibrahim Azar, Stephani Wang, Vikram Dhillon, Jacqueline Kenitz, Dawn Lombardo, Roderick Deano, Syed Mahmood, Hirva Mamdani, Anthony F. Shields, Philip Agop Philip, Michael Stellini, Joshua Schulman-Marcus
Publikováno v:
Palliative Medicine Reports, Vol 3, Iss 1, Pp 279-286 (2022)
Background: With recent improvements in survival of cancer patients and common use of high-value care at end of life, the management of cardiovascular disease (CVD) in patients with cancer is increasingly important. To our knowledge, there are no cur
Externí odkaz:
https://doaj.org/article/7bb758b2746840bdb14383a1e658bbfd
Autor:
Robert Hsu, Denaly Chen, Bing Xia, Rebecca Feldman, Wendy Cozen, Luis E. Raez, Hossein Borghaei, Chul Kim, Misako Nagasaka, Hirva Mamdani, Ari M. Vanderwalde, Gilberto Lopes, Mark A. Socinski, Antoinette J. Wozniak, Alexander I. Spira, Stephen V. Liu, Jorge J. Nieva
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
BackgroundThe incidence of lung cancer in the US has been decreasing but a bigger decline has been observed in men despite similar declines in tobacco use between men and women. Multiple theories have been proposed, including exposure to exogenous es
Externí odkaz:
https://doaj.org/article/7acf7bf812854a01ad8168ea2aac8e7a
Autor:
Aliccia Bollig-Fischer, Bin Bao, Morenci Manning, Greg Dyson, Sharon K. Michelhaugh, Sandeep Mittal, Gerold Bepler, Hirva Mamdani
Publikováno v:
Molecular Biomedicine, Vol 2, Iss 1, Pp 1-12 (2021)
Abstract The development of targeted therapies that inhibit cancer-driving oncogenes has improved outcomes of patients diagnosed with lung adenocarcinoma (LUAD). In contrast, patients diagnosed with lung squamous cell carcinoma (LUSC) suffer worse su
Externí odkaz:
https://doaj.org/article/bf73dbc5835f4aecab19b61b3d06cd47
Autor:
Christine M. Bestvina, MD, Jennifer G. Whisenant, PhD, Valter Torri, MD, Alessio Cortellini, MD, Heather Wakelee, MD, Solange Peters, MD, PhD, Elisa Roca, MD, PhD, Alessandro De Toma, MD, Fred R. Hirsch, MD, Hirva Mamdani, MD, Balazs Halmos, MD, Oscar Arrieta, MD, Anne-Cecile Metivier, MD, Mary J. Fidler, MD, Jacobo Rogado, MD, Carolyn J. Presley, MD, MHS, Celine Mascaux, MD, Carlo Genova, MD, PhD, Juan Bautista Blaquier, MD, Alfredo Addeo, MD, Giovanna Finocchiaro, MD, Hina Khan, MD, Julien Mazieres, MD, PhD, Floriana Morgillo, MD, PhD, Jair Bar, MD, Avinash Aujayeb, MBBS, Giannis Mountzios, MD, PhD, Vieri Scotti, MD, Federica Grosso, MD, Erica Geraedts, MD, Ardak N. Zhumagaliyeva, MD, PhD, Leora Horn, MD, Marina Chiara Garassino, MD, Javier Baena, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 8, Pp 100335- (2022)
Introduction: The Thoracic Centers International coronavirus disease 2019 (COVID-19) Collaboration (TERAVOLT) registry found approximately 30% mortality in patients with thoracic malignancies during the initial COVID-19 surges. Data from South Africa
Externí odkaz:
https://doaj.org/article/40def45b1dee4cd69aa88c393bc82c35